Eli Lilly secures exclusive rights to chronic pain treatment
American pharmaceutical company Eli Lilly has secured an exclusive licence for a non-opioid, non-addictive chronic pain treatment from Boston-based biotech company Centrexion Therapeutics.
University of California settles licensing dispute with professor
The University of California has settled a dispute over the use of a diagnostic tool in graduate research projects.
Boehringer teams up with Gubra to develop second obesity treatment
German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.
Celgene takes action against alleged cybersquatter
US biotechnology company Celgene has taken legal action against the registrant of a domain name which allegedly infringes Celgene’s trademarks.
Sensorion in gene therapy collaboration with Institut Pasteur
Biopharmaceutical company Sensorion has entered into a research collaboration with French research body Institut Pasteur.
BGI takes Illumina to court over patent infringement in US
A subsidiary of China-based genome sequencing company BGI has filed a patent infringement suit against a US competitor.
GSK settles TM suit over dry-mouth product
GSK has entered into a settlement agreement with California-based Laclede, ending a trademark infringement dispute between the pair.
University of California granted fifth CRISPR patent
The US Patent and Trademark Office has issued a new CRISPR/Cas9 patent to the University of California, the University of Vienna and microbiologist Emmanuelle Charpentier.
CMA accuses 4 pharma companies of anti-competitive conduct
Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.
‘Considerable increase’ in pay-for-delay settlements: FTC report
The number of ‘pay-for-delay’ patent settlements reached in fiscal year 2016 represented a “considerable increase” from the previous year, according to a Federal Trade Commission report released yesterday, May 23, though there has been a considerable reduction in the most problematic settlements since 2013.
